External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Haematology ASH 2025
Roche and Genentech at

ASH 2025

December 06 - December 09
Orlando, USA
hematology.org
We will be contributing to topics related to
Haematology Oncology
Add to calendar
Share feedback
Share page
-
Agenda
Medical Materials
02:30 PM
Duration 15mins Room: OCCC - Tangerine Ballroom F1
Transcriptional profiling refines DLBCL classification and identifies subtypes with distinct therapeutic vulnerabilities
Godfrey J, Tumuluru S, Cooper A, Salles G, Trneny M, Lenz G, Morschhauser F, Jardin F, Harris W, Balasubramanian S, Sugidono M, Batlevi CL, Jiang Y, Kline J, Herrera A
Oncology | Diffuse large B cell lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:45 PM
Duration 15mins Location: OCCC - Tangerine Ballroom F2
Fixed treatment duration subcutaneous mosunetuzumab▼ monotherapy in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma: Interim results from the Phase II MorningSun study
Sharman JP, Tun AM, Villasboas JC, Ayed A, Jani P, Biondo JML, Wu M, Hossain F, Mun Y, Chopra VS, Farighi R, Misleh J, Peles S, Flinn IW, Burke JM
Oncology | Diffuse large B cell lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:45 PM
Duration 15mins Room: OCCC - Tangerine Ballroom F2
Mosunetuzumab▼ (Mosun) or glofitamab▼ (Glofit) in combination with golcadomide (Golca) demonstrates a manageable safety profile and encouraging efficacy in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL)
Andreadis C, Avivi I, Goldschmidt N, Townsend W, Bastos-Oreiro M, Avigdor A, Riedell PA, Tzoran I, Eyre TA, McKay P, Abrisquesta P, Gonzales Barca E, Martin Garcia-Sancho A, Galimberti S, Kwan A, Relf J, Leung W, Mussai F, Ma CY, Petel A, Muller PY, Hou X, Fox CP
Oncology - Haematology | Non Hodgkin Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
08:15 PM
Duration 15mins Room: OCCC - West Hall D1
Tumor clearance, T-cell fitness and minimal residual disease (MRD) outcomes in patients with relapsed/refractory multiple myeloma (RRMM) treated with cevostamab plus pomalidomide and dexamethasone: Biomarker analyses from CAMMA 1 Arm B
Harrison S, Hasselbalch Riley C, Mian HS, Spencer A, Lavi N, Paris L, Mihalyova J, Popat R, Szarejko M, Grosicki S, Kim K, Sandhu I, Chebon S, Tyagi T, Sewpaul P, Richardson L, Trunzer K, Mishra A, Trudel S
Oncology | Multiple Myeloma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 15mins Room: OCCC - Tangerine Ballroom F2
Fixed-duration subcutaneous (SC) mosunetuzumab▼, with maintenance therapy, in patients (pts) with previously untreated high-tumor burden follicular lymphoma (HTB FL): Longer follow-up and exploratory circulating tumor (ct)DNA analysis of the Phase II MorningSun study
Burke JM, Sharman JP, Anz B, Zuniga R, Tun AM, Wright D, Jani P, Biondo JML, Wu M, Mun Y, Chopra VS, Farighi R, Villasboas JC, Budde LE, Flinn IW
Oncology | Follicular Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
09:00 PM
Duration 15mins Room: OCCC - W304ABCD
NXT007 prophylaxis in people with hemophilia A with or without FVIII inhibitors: a global phase I/II multiple-ascending-dose study
Mancuso ME, Matino D, Hart D, López-Jaime FJ, Schmitt C, Shapiro A, Ventriglia G, Kiialainen A, Young L, Catalani O, Belletrutti M, Chu T, Windyga J, Jiménez-Yuste V, Lehle M, Staber JM
Haematology | Hemophilia A

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
10:30 PM
Duration 120mins Orlando, USA
Inequity in travel burden among patients receiving bispecific antibodies (BsAbs) for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): a real-world study of Medicare beneficiaries in the United States (US)
Frosch Z, Masaquel A, Ma E, Zuk E, Davis M, El Moustaid F, Wu M, Reyes C, Cassoli L, Huntington SF
Oncology | Diffuse large B cell lymphoma - Follicular Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 120mins Orlando, USA
Economic and Clinical Impact of Emicizumab in People With Moderate and Severe Hemophilia A in the US
Lee JS, El Moustaid F, Lee L
Haematology | Hemophilia A

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 120mins Orlando, USA
Evolution of joint health and physical activity in people with hemophilia A without factor VIII inhibitors switching to emicizumab prophylaxis: A second interim analysis of the BEYOND ABR study
Kruse-Jarres R, Castaman G, Di Minno MND, Stephensen D, Lobet S, Barlera S, Brocchieri C, Jiménez-Yuste V
Haematology | Hemophilia A

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 120mins Orlando, USA
Promising response rates and manageable safety with mosunetuzumab▼ plus lenalidomide (Mosun-Len) in patients with relapsed/refractory (R/R) follicular lymphoma (FL): US extension cohort from the Phase III CELESTIMO study
Sano D, Bartlett N, Budde LE, Brinker B, Vaidya R, Babu S, Diefenbach C, Nze C, Ma CY, Knapp A, Doral MY, Chen V, Hauser P, Wei MC, Moorthy P, Phillips A, Surh N, Jan A, Purev E, Wagner-Johnston N
Oncology | Follicular Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 120mins Orlando, USA
Effects and interferences of NXT007, a novel bispecific antibody, on coagulation assays
Kiialainen A, Hart D, Schmitt C, Locke M
Haematology | Hemophilia A

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 120mins Orlando, USA
Fixed-duration subcutaneous mosunetuzumab▼ demonstrates sustained clinically meaningful outcomes in patients with previously untreated, low-tumor burden follicular lymphoma
Villasboas JC, Burke JM, Tun AM, Liu S, Sharman JP, Biondo JML, Jani P, Wu M, Mun Y, Chopra VS, Farighi R, Munoz J, Yunus F, Flinn IW, Budde LE
Oncology | Follicular Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
10:15 PM
Duration 15mins Room: OCCC - W224ABEF
Long-term immune reconstitution and final 1-year follow-up after fixed-duration venetoclax-obinutuzumab (VenO) in first-line (1L) chronic lymphocytic leukemia (CLL): results from the Phase III CRISTALLO trial
Jin HY, Sharman JP, Laurenti L, Ferrant E, Casado Montero LF, Mulligan SP, Harrup R, Opat S, Ibatici A, Marasca R, Sportoletti P, Egginton A, Thadani-Mulero M, Cazares O, Jiang Y, Boyer M, Morschhauser F
Oncology | Chronic Lymphocytic Leukemia

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 15mins Room: OCCC - West Hall E1
Subcutaneous cevostamab demonstrates manageable safety and clinically meaningful activity in relapsed/refractory multiple myeloma (RRMM): First results from the Phase Ib CAMMA 3 study
Ho PJ, Quach H, Delimpasi S, Santoro A, Lee C H-S, Kint N, Faict S, Yu Y, Catalani O, Mishra A, Tyagi T, Devlin C, Sheikh S, Dimopoulos M
Oncology | Multiple Myeloma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
11:00 PM
Duration 120mins Orlando, USA
Treatment inequities in newly diagnosed diffuse large B-cell lymphoma (DLBCL): Comparing polatuzumab vedotin▼ in combination with rituximab, cyclophosphamide, doxorubicin and prednisone (Pola-R-CHP) vs rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) among Medicare beneficiaries
Vaughn J, Masaquel A, Reyes C, Hossain F, Zuk E, Straubing R, Davis M, Huntington SF
Oncology | Diffuse large B cell lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 120mins Orlando, USA
Real-world effectiveness of polatuzumab vedotin▼ plus rituximab▼, cyclophosphamide, doxorubicin and prednisone (R-CHP) compared with rituximab▼, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) among elderly Medicare beneficiaries with diffuse large B-cell lymphoma (DLBCL) in the United States
Matasar M, Masaquel A, Reyes C, Hossain F, Zuk E, Straubing R, Davis M, Huntington SF
Oncology | Diffuse large B cell lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 120mins Orlando, USA
Estimated total cost of care and patient out-of-pocket cost savings with first-line fixed duration venetoclax + obinutuzumab compared with treat-to-progression BTKi regimens among Medicare-eligible patients with chronic lymphocytic leukemia in the United States following the Inflation Reduction Act
Li SS, Rosettie KL, Manzoor BS, Reyes C, El Moustaid F
Oncology | Chronic Lymphocytic Leukemia

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 120mins Orlando, USA
Real-World Treatment Patterns for Hemophilia A Since the Launch of Emicizumab in the US
Lee JS, Schuldt R, Lee L
Haematology | Hemophilia A

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 120mins Orlando, USA
RESHAPE: A non-interventional study of real-world treatment patterns and outcomes across age groups in people with severe hemophilia A in Latin America, Eastern Europe, Africa, Asia, and the Middle East
Lemos García F, Zortel M, Demyanov A, Ramos Mejia I, Tobaruela G, Gondos A, Petrov V, Khoubila N
Haematology | Hemophilia A

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 120mins Orlando, USA
Glofitamab▼ plus gemcitabine and oxaliplatin (GemOx) vs rituximab (R)-GemOx in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Efficacy and safety in patient subgroups
Abdulhaq H, Townsend W, Ku M, Gregory GP, Abramson JS, Huang HQ, Zhang H, Yoon DH, Kim WS, Ghesquieres H, Hertzberg M, Zhang QY, Kesavan M, Mulvihill E, Kallemeijn MJ, Ta R, Choeurng V, Lundberg L, Fox CP
Oncology | Diffuse large B cell lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 120mins Orlando, USA
Fixed-duration intravenous mosunetuzumab▼ plus polatuzumab vedotin▼ combination therapy continues to demonstrate durable responses in patients with large B-cell lymphoma: 3-year follow-up from a Phase Ib/II study
Kamdar M, Chavez JC, Olszewski AJ, Assouline S, Lossos IS, Diefenbach C, Modi D, Sabry W, Naik S, Mehta A, Makadia S, Pham S, Penuel E, Wu H, Ead WS, To I, Houston DJ, Batlevi CL, Budde LE
Oncology | Non-Hodgkin Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 120mins Orlando, USA
A single-cell co-expression score (scDEL) of MYC and BCL2 identifies high-risk BCR-addicted DLBCL benefiting from polatuzumab vedotin▼ in the POLARIX trial
Sridhar S, Harris W, Tipgomut C, Pan-Hammarstrom Q, Salles G, Herrera A, Trněný M, Morschhauser F, Sugidono M, Batlevi CL, Jiang Y, Lenz G, Jeyasekharan A
Oncology - Haematology | Diffuse large B cell lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 120mins Orlando, USA
Pregnancy Outcomes After Crovalimab▼ Exposure: Analysis of Animal Model and Clinical Trial Data Suggest No Adverse Effects in Paroxysmal Nocturnal Hemoglobinuria
Nur E, Lin Z, Bopst M, Li S, Sreckovic S, Han B
Haematology | Paroxysmal Nocturnal Hemoglobinuria

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
10:45 PM
Duration 15mins Room: OCCC - Tangerine Ballroom F1
Long-term follow-up with sustained progression-free survival (PFS) benefit after subcutaneous (SC) mosunetuzumab▼ in combination with polatuzumab vedotin▼ compared with rituximab plus polatuzumab vedotin▼ in patients with relapsed or refractory (R/R) B-cell non-Hodgkin Lymphoma
Ghosh N, Chavez JC, Bastos-Oreiro M, Diefenbach C, Lossos IS, Shah NN, Assouline S, Olszewski AJ, Naik S, Pham S, Wei MC, Batlevi CL, To I, Ead WS, Makadia S, Penuel E, Budde E
Oncology | Non-Hodgkin Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 15mins Room: OCCC - Sunburst Room (W340)
Preclinical evaluation of SPK-8011QQ, an adeno-associated virus gene therapy for people with hemophilia A leveraging the dirloctocogene samoparvovec platform encoding an activated protein C-resistant B-domain deleted factor VIII
Frey N, Receveur N, Enderlin-Paput M, Blanchard EL, Hanby H, Ramos J, David T
Haematology | Hemophilia A

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
11:00 PM
Duration 120mins Orlando, USA
Differences in patient-reported time toxicity between bispecific antibody (BsAb) options: impact of treatment duration and dosing frequency on patient-reported time burden in relapsed/refractory (R/R) follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL)
Major A, Ma E, Masaquel A, Tsang M, Di M, Kaur S, Pophali P, Werner S, Bungay R, Latrémouille-Viau D, Guerin A, Reyes C, Wu M, Cassoli L, Torka P
Oncology | Diffuse large B cell lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 120mins Orlando, USA
Patient characteristics and treatment outcomes with Pola-R-CHP: a real-world study of patients with previously untreated diffuse large B-cell lymphoma (DLBCL) in the United States (US)
Reagan P, Shamas N, Masaquel A, Hossain F, Sa A, Li S, Mun Y, Chayab L, Perez L, Reyes C, Shewade A, Landsburg D
Oncology | Diffuse large B cell lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 120mins Orlando, USA
Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) preferred fixed-duration treatments with less frequent administrations in the era of novel bispecific antibodies (BsAbs)
Frosch Z, Masaquel A, Fox D, Reyes C, Cassoli L, Lai D, Myers K, Bussberg C, Patel K
Oncology | Diffuse large B cell lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 120mins Orlando, USA
Exploratory analysis from HAVEN 1–4 to further contextualize injection-site reactions among people with hemophilia A receiving emicizumab
Bloomberg M, Eakle K, Niggli M, Dhalluin C, Lee L, Lim E, Carpenter SL
Haematology | Hemophilia A

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 120mins Orlando, USA
Use of emicizumab in patients with acquired hemophilia A: an interim safety analysis of a large-scale post-marketing surveillance study
Shima M, Fukutake K, Ogawa Y, Kamei Y, Sugita C, Yuri A, Kobayashi R, Ioka A, Matsushita T
Haematology | Hemophilia A

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 120mins Orlando, USA
Glofitamab▼ in combination with polatuzumab vedotin▼ demonstrates high and durable efficacy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in the second-line (2L) and third-line and later (3L+) setting: A subgroup analysis
Hutchings M, Sureda A, Bosch F, Stauffer Larsen T, Corradini P, Avigdor A, Terol MJ, Rueda Dominguez A, Pinto A, Skarbnik A, Cordoba R, Jørgensen J, Zinzani PL, Gurion R, Goldschmidt N, Leung W, Li D, Relf J, Kallemeijn MJ, Sellam G, Gritti G
Oncology | Non-Hodgkin Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 120mins Orlando, USA
Sustained clinical benefit of glofitamab▼ plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO
Abramson JS, Ku M, Fox CP, Huang HQ, Zhang H, Townsend W, Yoon DH, Kim WS, Abdulhaq H, Herbaux C, Zaucha JM, Chang H, Mulvihill E, Kesavan M, Kallemeijn M, Ta R, Choeurng V, Bottos A, Lundberg L, Gregory GP
Oncology | Diffuse large B cell lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 120mins Orlando, USA
Fixed treatment duration mosunetuzumab▼ continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies: 5-year follow-up of a pivotal Phase II study
Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Kuruvilla J, Kim W, Cheah CY, Shadman M, Dietrich S, Ku M, El-Sharkawi D, Gutierrez N, Wei MC, Yin S, Sit J, Tracy S, Sabalvaro F, Penuel E, Bartlett NL
Oncology | Follicular Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 120mins Orlando, USA
Fixed-duration subcutaneous mosunetuzumab▼ continues to demonstrate high rates of durable responses in patients with relapsed/refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal Phase II study
Assouline S, Bartlett NL, Sehn LH, Giri P, Kuruvilla J, Schuster SJ, Yoon SS, Fay K, Hess G, Dreyling M, Gutierrez NC, Cybulski E, Sabalvaro F, Penuel E, Tracy S, Kuruvilla D, Chen J, Wiebking V, Wei MC, Budde LE
Oncology | Follicular Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 120mins Orlando, USA
Improvements in health-related quality of life (HRQoL) in the SUNMO study: subcutaneous (SC) mosunetuzumab▼ plus polatuzumab vedotin▼ (Mosun-Pola) vs rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after at least one prior therapy
Budde LE, Westin J, Zhang H, Maruyama D, Rego EM, Hong H, Goto H, Fesler M, Goodgame B, Li Z, Olszewski A, Ashby J, Yin S, Ead W, Janousek M, Pham S, Batlevi CL, Wei MC, Kim W
Oncology | Non-Hodgkin Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 120mins Orlando, USA
Pharmacodynamic biomarkers in people with hemophilia A receiving multiple ascending doses of NXT007
Kiialainen A, Schmitt C, Matino D, Staber JM, Mancuso ME, Jiménez-Yuste V, Windyga J, Shapiro A, Locke M, Hart D
Haematology | Hemophilia A

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 120mins Orlando, USA
Assessment of the prognostic value of FDG PET-derived markers and responses in POLARIX
Cottereau A-S, Herrera AF, Tilly H, Salles G, Chartier L, Sugidono M, Jemaa S, Carano RAD, Batlevi CL, Hapgood G, Lenz G, Morschhauser F
Oncology - Haematology | Diffuse large B cell lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 120mins Orlando, USA
Outcomes of CAR T-cell therapies after prior treatment with fixed-duration mosunetuzumab▼ in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
Braun A, Bartlett NL, Chihara D, Nastoupil LJ, Shadman M, Tzachanis D, Cochran H, Huang JJ, Wu M, Wei MC, Yin S, Hao JQ, Zhu Q, Mun Y, Budde LE
Oncology - Haematology | Non Hodgkin Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 120mins Orlando, USA
Diverse preferences for treatment options in relapsed/refractory (R/R) follicular lymphoma (FL): Survey results from patients in the United States (US)
Patel K, Ma E, Wu M, Myers K, Bussberg C, Galinsky J, Frosch Z
Oncology | Follicular Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Coming soon

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.